Parkinson's Disease
Conditions
Keywords
Idiopathic early, Parkinson's Disease
Brief summary
The investigators prospectively enrolled 64 early PD patients (less than 3 years after the first symptom) in order to prospectively assess the natural history of non-dopaminergic symptoms.
Detailed description
Patients were evaluated at baseline and after 2 years in off drug condition. Clinical, psychological, neuropsychological evaluations, functional respiratory evaluation, swallowing video fluoroscopy, dysarthria, gait and axial disorders.
Interventions
natural history of non dopaminergic signs
Sponsors
Study design
Eligibility
Inclusion criteria
* idiopathic parkinson's disease
Exclusion criteria
* dementia * severe axial gait disorders * respiratory or ENT pathology * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| dysarthria severity assessed by the BECD scale | 2 years | BECD (French battery of clinical evaluation of the dysarthria) is a validated scale for qualitative assessment of dysarthria severity in neurological disorders, especially PD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| swallowing function | 2 years | 150 mL glass of water test video fluoroscopy of swallow in off drug condition face and profile incidences: qualitative analysis of oral, pharyngeal, aspiration if necessary blindly assessed by 2 ENT experts in PD |
| gait axial function (freezing) | 2 years | SWS test rhythmic tests for differens imposed frequencies (upper lower limb and facial) kinematic analysis of gait parameters by VICON (oxford metrics) |
| Mattis scale | 2 years | — |
| LARS scale | 2 years | — |
| respiratory insufficiency detection | 2 years | pulmonary function tests include spirometry with standard spirometer and maximal inspiratory and expiratory flow volume curves . At least 3 reproductible F-V curves are necessary. Values of FCV, FEV, peak expiratory flow, peak inspiratory flow, forced expiratory flow, SNIP were measured 12 hours after last levodopa intake (off drug) |
| PAS scale | 2 years | — |
| MoCA | 2 years | — |
| Genetic Polymorphisme | 2 years | To evaluate of cognitive and profile correlation to the polymorphisms of COMT (catechol-O-methyltransferase: Val158Met COMT) of MAPT H1 / H2 (microtubule associated tau protein) and ApoE (Apolipoprotein-E-ε2, 3, 4 ) |
| MADRS scale | 2 years | — |
Countries
France